Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Only the adverse events affecting skin, subcutaneous tissue and skin appendages (also known as ‘skin toxicity’ or ‘skin changes’) secondary to EGFRI treatment are addressed on this website. This section of the website, ‘Prophylaxis and treatment’, comprises the following sub-sections:

  • What Healthcare Professionals should know: the key treatment principles for EGFRI-related skin toxicities.
  • What Patients can do: the key behavioural and prophylactic measures that can be undertaken by patients to minimise EGFRI-associated cutaneous changes.
  • Prophylactic management: therapeutic principles against EGFRI-associated skin toxicities that target early pathogenic mechanisms thereby helping to minimise the grade and extent of toxicities.
  • Reactive management: the necessity for close monitoring of and early, as well as specific, intervention in EGFRI-associated skin toxicities.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings